Thermodynamic factors (supersaturation of substances that form crystals) and kinetic factors (heterogeneous nucleants and crystallization inhibitors) affect the formation of crystals and stones in the urinary tract. We studied the effect of five different polyhydroxycarboxylic acids and phytate on the formation of calcium oxalate crystals in artificial urine. All tested molecules are known to inhibit the crystallization of this calcium salt, and to also form complexes with calcium ions. Considering the typical concentration of polyhydroxycarboxylic acids in urine (similar to that of the calcium ion) and their ability to inhibit crystallization, their most important effect is the capacity to complex calcium—a thermodynamic effect. For phytate and its metabolites, which are present in concentrations much lower than that of the calcium ion, the most important effect is as a crystallization inhibitor—a kinetic effect. Among the five polyhydroxycarboxylic acids examined here, hydroxycitrate had the strongest complexing capacity, and the addition of phytate to hydroxycitrate led to greater inhibition of crystallization. Therefore, because oral consumption of hydroxycitrate does not increase the urinary pH, it is likely that the combined consumption of hydroxycitrate and phytate can provide certain benefits for patients with increased risk of developing calcium oxalate stones. We also discussed the effects of these different molecules on the different calcium oxalate stones, including papillary calcium oxalate monohydrate stones, cavity calcium oxalate monohydrate stones, calcium oxalate dihydrate stones, and mixed calcium oxalate dihydrate/hydroxyapatite stones.
Background: Common forms of pathological crystals are uric acid or urates, which are responsible for gout, urolithiasis, and other conditions. Methods: We used a kinetic–turbidimetric crystallization assay to evaluate the effect of ten specific methylxanthines on the crystallization of monosodium urate, potassium urate, and ammonium urate in conditions that mimicked urine. We also studied the effect of different levels of 7-methylxanthine in the presence of other biological compounds (albumin and hyaluronic acid) on the solubility of monosodium urate in conditions that mimicked synovial fluid. Results: The results showed that 7-methylxanthine in the range of 16.61–49.84 mg/L inhibited the crystallization of each urate when the initial urate concentration was 3 × 10−3 M (500 mg/L) and the conditions mimicked urine, and that the greatest inhibitory effect was for monosodium urate. In addition, 7-methylxanthine at a concentration of 25 mg/L totally prevented the crystallization of monosodium urate at an initial urate concentration of 2.38 × 10−3 M (400 mg/L) in conditions that mimicked synovial fluid. Moreover, at a low concentration of 7-methylxanthine, albumin and hyaluronic acid increased this inhibitory effect. Conclusions: Our in vitro results demonstrate that 7-methylxanthine inhibits the crystallization of urates in conditions that mimic synovial fluid and urine.
Background/Objectives: 7-Methylxanthine (7-MX) is a naturally occurring metabolite of caffeine and theobromine that can inhibit the crystallization of monosodium urate (MSU) and may be useful for the prevention or treatment of gout. However, the pharmacokinetics and ex vivo activity of 7-MX remain poorly characterized. Methods: The present study assessed the pharmacokinetics of 7-MX in Sprague Dawley rats following a single oral dose (30 mg/kg), and the ex vivo inhibition of MSU crystallization by 7-MX in rat plasma after the repeated administration of oral 7-MX. Results: The pharmacokinetic analysis showed that 7-MX reached peak plasma concentration (Cmax ≈ 30 µM) at 30 min after administration (tmax), the terminal half-life was approximately 1.4 h, and there was no evidence of accumulation after repeated daily dosing. After repeated administration, the relationship between dose (30 or 60 mg/kg) and plasma concentration was proportional. In vitro and ex vivo crystallization assays demonstrated that 7-MX inhibited MSU crystallization in a concentration-dependent manner. The in vitro studies showed that 100 µM 7-MX inhibited up to 74% of MSU crystallization under supersaturated conditions (400 mg/L urate). The ex vivo experiments indicated that plasma from rats that received 30 or 60 mg/kg of 7-MX had 41.4% and 52.6% inhibition of crystallization, consistent with the measured plasma concentrations. Conclusions: These findings confirm that oral administration of 7-MX to rats led to a plasma level that was sufficient to decrease MSU crystallization in plasma, and there were no observable toxicities. These results support the potential of 7-MX as a safe oral treatment for gout, especially in combination with urate-lowering therapies, such as allopurinol. Further clinical investigations are warranted to confirm the therapeutic potential of 7-MX in humans.
This in vitro study examined the influence of supersaturation level on the efficacy of different inhibitors in preventing the crystallization of calcium oxalate, uric acid, and cystine. Kinetic–turbidimetric assays were used to determine the induction time of crystallization (ti) in the absence and presence of different inhibitors. For calcium oxalate, the inhibitory effects of citrate, hydroxycitrate, tartronate, and phytate decreased significantly as the Ca2+ concentration increased from 220 mg/L to 240 mg/L. The polyhydroxycarboxylic compounds (citrate, hydroxycitrate, tartronate) can form complexes with calcium ions, decreasing overall supersaturation. Even though phytate also forms complexes with calcium, its urinary concentration is much lower than that of calcium, so the decrease in supersaturation can be considered negligible. For uric acid, theobromine and two of its metabolites (3-methylxanthine and 7-methylxanthine) inhibited the formation of these crystals. For each compound, the efficacy of inhibition decreased as the supersaturation of uric acid increased. For cystine, the inhibitory effect of N-acetylcysteine was lower at pH 4.5 and 5.0 than at pH 6.0. These studies of the crystallization of calcium oxalate, uric acid, and cystine showed that the efficacy of crystallization inhibitors decreased as the level of supersaturation increased. The results demonstrate that, in patients prone to kidney stone formation, the effectiveness of crystallization inhibitors can be improved by reducing the supersaturation of the specific stone-forming compound.